Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer.
chemotherapy
gallbladder cancer
immune cells
immune index
tumor microenvironment
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
31
07
2019
revised:
22
10
2019
accepted:
25
10
2019
pubmed:
16
11
2019
medline:
14
1
2020
entrez:
16
11
2019
Statut:
ppublish
Résumé
Use of immune index is a new potential approach for cancer classification and prediction. To investigate the status and clinical effect of immune index in gallbladder cancer (GBC), 238 GBC patients from Zhongshan Hospital affiliated to Fudan University were involved in the present study, including 113 patients in a training set and 125 patients in a validation set. Five immune cells (macrophages, neutrophils, regulatory T cells, cytotoxic T cells and mast cells) were selected based on a literature review and the immune index for each patient was calculated using the LASSO regression. A low immune index (<1) was defined as immunotype A and a high immune index (≥1) was defined as immunotype B. The 5-year overall survival rate for immunotype A was higher than that for immunotype B in the training set and the validation set (70.0% vs 37.0%, P < 0.001; 68.9% vs 47.5%, P = 0.002; respectively). Moreover, the immune index showed higher prediction efficiency compared with all the single immune cells which we selected. When combined with the immune index, the areas under the curve (AUC) of the TNM staging system in both sets were elevated from 0.677 to 0.787 and from 0.631 to 0.694, respectively. Interestingly, gemcitabine-based chemotherapy only benefits stage II patients of immunotype B and stage III patients of both immunotype A and immunotype B (P = 0.015, P = 0.030, P = 0.011, respectively) but does not work in stage II patients of immunotype A (P = .307). Taken together, the immune index could effectively predict prognosis and the benefits of gemcitabine-based chemotherapy and might improve on the TNM staging system.
Identifiants
pubmed: 31729088
doi: 10.1111/cas.14239
pmc: PMC6942443
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
219-228Subventions
Organisme : National Natural Science Foundation of China
ID : 81872352
Organisme : National Natural Science Foundation of China
ID : 81600630
Organisme : Foundation of Shanghai Science and Technology Committee
ID : 16411952000
Organisme : JianFeng Project of XuHui Provincial Commission of Health and Family Planning
ID : SHXH201703
Organisme : Shanghai Medical Discipline of Key Programs for General Surgery
ID : 2017ZZ02007
Informations de copyright
© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
CA Cancer J Clin. 2001 Nov-Dec;51(6):349-64
pubmed: 11760569
Br J Cancer. 2015 Dec 22;113(12):1677-86
pubmed: 26645238
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Clin Cancer Res. 2018 Jul 1;24(13):3069-3078
pubmed: 29514839
Proc Natl Acad Sci U S A. 2016 Jul 5;113(27):7383-90
pubmed: 27382153
Gastroenterology. 2018 May;154(6):1647-1659
pubmed: 29366842
Nature. 2019 Aug;572(7769):392-396
pubmed: 31367043
Nature. 2019 Oct;574(7776):45-56
pubmed: 31578484
Sci Transl Med. 2017 Jan 11;9(372):
pubmed: 28077684
J Clin Oncol. 2019 Mar 10;37(8):658-667
pubmed: 30707660
EMBO J. 2015 Sep 2;34(17):2219-36
pubmed: 26136213
Cancer Cell. 2014 Nov 10;26(5):623-37
pubmed: 25446896
Nat Rev Immunol. 2016 Oct;16(10):599-611
pubmed: 27526640
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Cancer Res Treat. 2015 Jul;47(3):343-61
pubmed: 25989801
Ann Surg Oncol. 2014 Jun;21 Suppl 3:S414-21
pubmed: 24566864
Nat Rev Cancer. 2004 Sep;4(9):695-706
pubmed: 15343276
Cancer Cell. 2018 Apr 9;33(4):547-562
pubmed: 29634943
J Surg Oncol. 2017 Apr;115(5):580-590
pubmed: 28138977
Nat Med. 2018 Aug;24(8):1143-1150
pubmed: 30038220
Cell. 2018 Jan 25;172(3):534-548.e19
pubmed: 29275861
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Immunol Res. 2015 May;3(5):518-25
pubmed: 25716473
Med Microbiol Immunol. 2015 Jun;204(3):327-34
pubmed: 25648117
Semin Immunol. 2018 Feb;35:29-34
pubmed: 29428698
Cancer Cell. 2012 Mar 20;21(3):309-22
pubmed: 22439926
Gastroenterology. 1998 Oct;115(4):937-46
pubmed: 9753497
Am J Gastroenterol. 2000 Jun;95(6):1402-10
pubmed: 10894571
Trends Immunol. 2012 Mar;33(3):119-26
pubmed: 22277903
Hepatobiliary Surg Nutr. 2014 Oct;3(5):221-6
pubmed: 25392833
Br J Cancer. 2014 Jul 29;111(3):430-6
pubmed: 24960403
Cell. 2017 May 4;169(4):750-765.e17
pubmed: 28475900
Nat Rev Immunol. 2017 Nov;17(11):703-717
pubmed: 28757603
Ann Oncol. 2014 Feb;25(2):391-8
pubmed: 24351397
Cancer Sci. 2018 Jul;109(7):2266-2274
pubmed: 29723922
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
Cancer Cell. 2015 Dec 14;28(6):785-799
pubmed: 26678340
Cell. 2019 Aug 8;178(4):933-948.e14
pubmed: 31398344
BMC Cancer. 2018 Mar 21;18(1):313
pubmed: 29562907
Ann Oncol. 2019 Feb 1;30(2):266-273
pubmed: 30445581
Ann Surg. 2018 Feb;267(2):311-318
pubmed: 27763900
J Transl Med. 2012 Jan 03;10:1
pubmed: 22214470
Physiol Rev. 2019 Apr 1;99(2):1223-1248
pubmed: 30758246
Trends Immunol. 2019 Mar;40(3):228-242
pubmed: 30777721
Nat Immunol. 2017 Sep;18(9):1004-1015
pubmed: 28759001
Immunity. 2019 Feb 19;50(2):302-316
pubmed: 30784578
Nat Immunol. 2010 Oct;11(10):889-96
pubmed: 20856220
N Engl J Med. 2010 Apr 8;362(14):1273-81
pubmed: 20375404
Nat Rev Cancer. 2016 Jul;16(7):431-46
pubmed: 27282249
Cancer Sci. 2020 Jan;111(1):219-228
pubmed: 31729088
Nat Rev Immunol. 2019 Jun;19(6):369-382
pubmed: 30718830
Nat Med. 2017 Apr;23(4):517-525
pubmed: 28288110